Table 3.

Factors Associated with Recurrence-Free and Overall Survival in All Patients

Variable	Univariate			Multivariable
	HR	95% CI	p Value	HR	95% CI	p Value
Recurrence-free survival
Age, y	1.0	1.0–1.0	0.22
Hormone secretion	1.6	1.1–2.4	0.03*	1.3	0.8–2.0	0.31
Familial syndrome	0.4	0.1–3.0	0.39
Intraoperative tumor rupture	1.6	0.8–3.0	0.16
Stage
I	1.0	Ref	Ref	1.0	Ref	Ref
II	1.4	0.5–4.2	0.50	1.5	0.4–5.0	0.53
III	2.8	1.0–7.8	0.06	2.7	0.8–9.1	0.10
IV	4.8	1.7–13.9	0.004*	4.0	1.2–14.0	0.03*
R1	0.7	0.4–1.2	0.14
Postoperative adrenal insufficiency	1.3	0.8–2.1	0.34
Complication	1.1	0.7–1.7	0.65
Adjuvant radiation	1.1	0.6–2.2	0.78
Adjuvant chemotherapy	1.4	0.8–2.4	0.19
Mitotane	1.8	1.2–2.7	0.01*	1.4	0.9–2.2	0.21
Overall survival
Age, y	1.0	1.0–1.0	0.79
Hormone secretion	1.7	1.1–2.6	0.01*	2.3	1.2–4.3	0.01*
Familial syndrome	0.9	0.2–3.8	0.91
Intraoperative tumor rupture	1.6	0.8–3.0	0.20
Stage
I	1.0	Ref	Ref	1.0	Ref	Ref
II	3.7	0.5–21.8	0.21	1.8	0.2–14.3	0.59
III	6.4	0.8–49.5	0.08	1.6	0.2–13.2	0.65
IV	17.3	2.3–132.3	0.01	7.9	1.0–63.9	0.05
R0	1.0	Ref	Ref	1.0	Ref	Ref
R1	2.8	1.8–4.6	<0.001*	2.8	1.5–5.4	0.002*
R2	4.3	2.0–9.3	<0.001*	4.4	1.3–14.5	0.02*
Postoperative adrenal insufficiency	1.5	0.9–2.5	0.17
Complication	1.8	1.1–2.9	0.03*	0.9	0.5–1.7	0.70
Adjuvant radiation	1.1	0.5–2.5	0.76
Adjuvant chemotherapy	1.7	1.0–2.8	0.048*	0.4	0.2–0.9	0.03*
Mitotane	1.8	1.2–2.8	0.01*	0.88	0.5–1.6	0.68

^*Significant.

HR, hazard ratio; R0, microscopically negative margin; R1, microscopically positive margin; R2, grossly positive margin; Ref, reference.